Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $16.00 price target on the biopharmaceutical company’s stock.

ESPR has been the subject of several other research reports. Needham & Company LLC dropped their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Stock Down 1.9 %

NASDAQ:ESPR opened at $2.07 on Friday. Esperion Therapeutics has a 52-week low of $0.87 and a 52-week high of $3.40. The stock has a fifty day simple moving average of $1.91 and a 200-day simple moving average of $2.13. The company has a market capitalization of $406.20 million, a PE ratio of -2.45 and a beta of 0.96.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analyst estimates of $51.90 million. As a group, equities analysts anticipate that Esperion Therapeutics will post -0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BOKF NA purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at $26,000. Xponance Inc. acquired a new position in shares of Esperion Therapeutics during the 2nd quarter valued at about $28,000. CVI Holdings LLC purchased a new position in shares of Esperion Therapeutics during the 1st quarter worth about $37,000. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $27,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Esperion Therapeutics in the first quarter valued at approximately $50,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.